Back

Prognostic Impact and Structural Recovery in HFrEF Patients on Vericiguat with PH and Tricuspid Regurgitation: Results from the VERISEC Registry

30 August 2026 (12:40 - 12:50)
Organised by: Logo
Congress Presentation Part of: From shock to recovery: rethinking risk, rhythm, and remodelling Ventricular Remodelling ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Alberto Esteban Fernandez

Severo Ochoa Hospital, Leganes (Spain)

5 More presentations in this session

Presentation thumbnail
Hybrid cardiac rehabilitation at anaerobic threshold reduces myocardial fibrosis and improves outcomes in HFrEF post-MI: a multicenter RCT
Doctor R. Ding (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
GDF-15 as an early marker for prognosis in patients with cardiogenic shock
Professor A. Schaefer (Hannover, DE)
Abstract Slides Video
Presentation thumbnail
Machine learning–based proteomic phenogrouping identifies an inflammatory high-risk subtype in HFpEF : results from the PACIFIC-PRESERVED study
Professor J. Hulot (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of percutaneous stellate ganglion block technique in patients with electrical storm complicated by cardiogenic shock
Doctor A. Morena (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Sex differences in infarct–related cardiogenic shock: a secondary analysis of the ECLS–SHOCK trial
Doctor M. Buske (Leipzig, DE)
Abstract Slides Video

Access the full session

Session thumbnail
From shock to recovery: rethinking risk, rhythm, and remodelling
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 12:40 CET
You may be interested in
thumbnail
Congress Presentation
Impact of targeted therapies withPDE5 inhibitors, endothelin receptor antagonists and sotatercept on functional tricuspid regurgitation in pulmonary arterial hypertension
30 August 2026
thumbnail
Congress Presentation
The enhanced HFrEF medication toolkit in practice
30 August 2026
thumbnail
Congress Presentation
Role of SGLT2I in improving right ventricular systolic function in patients with HFpEF
28 August 2026
thumbnail
Congress Presentation
Cardiac reverse remodelling of left heart during vericiguat therapy for high-risk HFrEF
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources